Intravascular Imaging System Articles & Analysis: Older
5 news found
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. ...
Through previous strategic acquisitions and partnerships, Nipro Corporation has bolstered its global footprint to include intravascular imaging technologies, vascular therapies, and breakthrough technologies. ...
The PROSPECT II study demonstrated the ability of near-infrared spectroscopy (NIRS) imaging plus intravascular ultrasound (IVUS) to identify coronary plaques responsible for future coronary events. ...
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indications for use for its Makoto Intravascular Imaging System. The approval is based on the ...
The LRP Study validates and expands upon these earlier studies through its larger size, rigorously pre-specified methods, and true focal vulnerable plaque based co-primary endpoints. Infraredx’s Makoto Intravascular Imaging System, with accompanying Dualpro IVUS+NIRS catheter, is the only technology on the market FDA-cleared for the ...